Dawnrays Pharmaceutical (Holdings) Limited

HKSE 2348.HK

Dawnrays Pharmaceutical (Holdings) Limited Return on Assets (ROA) for the year ending December 31, 2023: 9.00%

Dawnrays Pharmaceutical (Holdings) Limited Return on Assets (ROA) is 9.00% for the year ending December 31, 2023, a -7.70% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Dawnrays Pharmaceutical (Holdings) Limited Return on Assets (ROA) for the year ending December 31, 2022 was 9.75%, a -9.10% change year over year.
Dawnrays Pharmaceutical (Holdings) Limited Return on Assets (ROA) for the year ending December 31, 2021 was 10.73%, a 16.15% change year over year.
Dawnrays Pharmaceutical (Holdings) Limited Return on Assets (ROA) for the year ending December 31, 2020 was 9.23%, a 0.73% change year over year.
Dawnrays Pharmaceutical (Holdings) Limited Return on Assets (ROA) for the year ending December 31, 2019 was 9.17%, a -28.64% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

HKSE: 2348.HK

Dawnrays Pharmaceutical (Holdings) Limited

CEO	Ms. Liwei Yu
IPO Date	July 11, 2003
Location	Hong Kong
Headquarters	CNT Tower
Employees	1,175
Sector	Healthcare
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. It operates in two segments, Intermediates and Bulk Medicines, and Finished Drugs. The company offers antibiotics, including pharmaceutical intermediates, bulk medicines, powder for injections, and oral antibiotics. It also provides and system specific medicines comprising cardiovascular systems; anti-allergic, anti-HBV, and digestive systems; urinary systems; and anti-pyretic analgesic, respiratory, and endocrine system drugs in the form of tablets, capsules, and granules. The company was founded in 1995 and is headquartered in Wan Chai, Hong Kong. Dawnrays Pharmaceutical (Holdings) Limited is a subsidiary of Fortune United Group Limited.

Key trends

Past 5 years